Business

Biotech

A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down

By Matthew Herper

Biotech

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By Adam Feuerstein

Biotech

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

By Jonathan Saltzman — Boston Globe

Dr. Patrick Soon-Shiong, Cancer MoonShot 2016

Biotech

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

By Rebecca Robbins

Biotech

3 trends in biotech to watch in 2020

By Damian Garde

Biotech

Sarepta sells international rights to Duchenne gene therapy to Roche

By Adam Feuerstein

Biotech

Ring Therapeutics is developing a new way to deliver gene therapy

By Jonathan Saltzman — Boston Globe

Business

The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

By Matthew Herper

Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Business

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

By Nicholas Florko

Biotech

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

By Erin Brodwin

Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

Biotech

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

By Adam Feuerstein

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

Business

How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy

By Matthew Herper

Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Business

Patient charity settles allegations it helped MS drug makers pay kickbacks

By Elizabeth Cooney

Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Politics

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Biotech

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

By Adam Feuerstein

How swallowing a star might keep you from missing a dose of medicine

‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices

All talk, no M&A makes for a down JPM Day

Agios CEO forecasts ‘line of sight’ to more approved drugs and profits

A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

3 trends in biotech to watch in 2020

Sarepta sells international rights to Duchenne gene therapy to Roche

Ring Therapeutics is developing a new way to deliver gene therapy

The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy

Global Blood secures FDA approval for new pill to treat sickle cell disease

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Patient charity settles allegations it helped MS drug makers pay kickbacks

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug